Format

Send to

Choose Destination
F1000Res. 2016 Jan 8;5:38. doi: 10.12688/f1000research.7599.1. eCollection 2016.

Rituximab efficiently depletes B cells in lung tumors and normal lung tissue.

Author information

1
Tumor Immunology group, Department of Pathology, Oslo University Hospital, Oslo, Norway; Centre for Immune Regulation, University of Oslo, Oslo, Norway.
2
Department of Pathology, Oslo University Hospital, Oslo, Norway.
3
Tumor Immunology group, Department of Pathology, Oslo University Hospital, Oslo, Norway; Centre for Immune Regulation, University of Oslo, Oslo, Norway; Department of Cardiothoracic Surgery, Oslo University Hospital, Oslo, Norway.
4
Betanien Hospital, Skien, Norway.
5
Department of Oncology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
6
Department of Oncology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway; Department of Cancer Genetics, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
7
Tumor Immunology group, Department of Pathology, Oslo University Hospital, Oslo, Norway; Centre for Immune Regulation, University of Oslo, Oslo, Norway; Department of Biosciences, University of Oslo, Oslo, Norway.

Abstract

Rituximab is a monoclonal antibody that targets the CD20 B-cell-specific antigen and is widely used as therapy for B-cell lymphoma. Since rituximab depletes both malignant and normal B cells, it is increasingly being used to treat various conditions in which normal B cells have a pathogenic role, such as rheumatoid arthritis and multiple sclerosis. It is well-established that rituximab efficiently eliminates B cells in blood, lymph nodes, and spleen. In contrast, the effect of rituximab in non-lymphoid tissues remains poorly documented and is debated. Here, we report a rheumatoid arthritis patient who was treated with rituximab before receiving thoracic surgery for non-small cell lung cancer. Using flow cytometry and immunohistochemistry, we show that rituximab efficiently depleted CD20-positive B cells in a primary lung tumor, in lung-associated lymph nodes, and in normal lung tissue. We conclude that rituximab may be very efficient at depleting normal B cells in the lungs. This property of rituximab may potentially be exploited for the treatment of conditions in which pathogenic B cells reside in the lungs. On the other hand, the clearance of lung B cells may provide an explanation for the rare cases of severe non-infectious pulmonary toxicity of rituximab.

KEYWORDS:

B cells; depletion; lungs; lymph node; monoclonal antibody; non-small cell lung cancer; rituximab; tumor

Supplemental Content

Full text links

Icon for F1000 Research Ltd Icon for PubMed Central Icon for Norwegian BIBSYS system
Loading ...
Support Center